Dosage schedule of gentamicin for chronic renal insufficiency in children

HAJIME YOSHIOKA, MASATOSHI TAKIMOTO, ICHIRO MATSUDA, AND SHINZABURO HATTORI

From the Departments of Paediatrics, Asahikawa Medical College, and Kumamoto University School of Medicine

SUMMARY  Gentamicin was given to paediatric patients with chronic renal disease complicated by infections by Gram-negative organisms, in which renal function varied from normal to severely insufficient. Peak serum levels after an intramuscular dose of 1 mg/kg body weight ranged from 3·1 to 9·4 μg/ml, which appeared adequate for therapy. The peak value was not related to the renal function of the individual patients.

The serum half-life of gentamicin correlated inversely with the value for endogenous creatinine clearance. A diagram for the estimation of the serum half-life of gentamicin using the creatinine clearance value is presented. As a practical guide, it is recommended that the dose of gentamicin in children with renal function impairment be 1 mg/kg given intramuscularly and that the interval between doses be almost three times as long as the serum half-life, which can be estimated by means of the diagram for individual patients. The accuracy and safety of this method were confirmed by treating children with this adjusted dosage schedule.

Because gentamicin is eliminated largely by renal function, toxic effects occur more easily in renal insufficiency than under conditions of normal renal function. On the other hand, gentamicin is frequently indicated in patients with renal impairment to combat infections due to Gram-negative organisms, which are apt to complicate haemodialysis and associated minor surgical procedures. In order to avoid toxicity, several approaches to adjusting dosages in patients with renal disease have been devised (Gingell and Waterworth, 1968; Gyselynck et al., 1971; McHenry et al., 1971; Chan et al., 1972; Cutler et al., 1972).

Since these studies were done almost exclusively on adult patients, a study was needed in paediatric patients. In this report we show firstly, the relationship of the rate of elimination of gentamicin from plasma to renal function in children, and secondly, we propose a schedule for modifying gentamicin dosage using a diagram. Gentamicin was administered to patients with renal insufficiency complicated by infection according to the adjusted dosage, and the accuracy and safety of the method were clinically confirmed.

Patients and methods
Fifteen patients with various renal diseases were studied. They ranged in age from 8 to 17 years and in weight from 23 to 60 kg. The renal functions of the patients were diverse, ranging from 5 to 148 ml/min per 1·73 m² of the body surface area in endogenous creatinine clearance (Ccr), and from 8·5 to 95·5 mg/100 ml (3·3–34 mmol/l) in blood urea nitrogen. Gentamicin was prescribed on clinical and bacteriological grounds and given intramuscularly in a dose of 1 mg/kg body weight.

Samples of peripheral blood were collected with appropriate time intervals before and after gentamicin injection. The serum was immediately separated by centrifugation and kept frozen until tested. Concentration of gentamicin in serum samples was determined by the well-plate agar method (Garrod et al., 1973) using Bacillus subtilis PCI 219 as the indicator strain. The half-life of gentamicin in the serum (T½) was estimated by means of the method of least squares. Data were plotted on log/log paper, and a diagram indicating the relation of T½ of gentamicin to Ccr was drawn.

Three patients were treated for infections due to Gram-negative organisms by an adjusted dose of gentamicin, using this diagram. Gentamicin was given to these patients in a dosage of 1 mg/kg, at intervals almost 3 times as long as the estimated T½. We measured peak levels, and the changes in blood level up to the fourth dose.
Dosage schedule of gentamicin for chronic renal insufficiency in children

Results

Correlation between renal function and serum half-life of gentamicin. The age, weight, clinical diagnosis, Ccr, peak serum levels, and estimated half-life of gentamicin in the serum of the 15 patients are listed in Table 1. Peak serum levels were attained 30 to 60 minutes after injection and ranged from 3·1 to 9·4 μg/ml. No appreciable differences were observed in peak serum levels among patients with normal and impaired renal function. A decline of serum concentration was thereafter delayed in patients with decreased renal function. The delay was likely to be proportional to the extent of renal damage. The T½ value increased sharply when Ccr values went below a level of 20 ml/min per 1·73 m² of the body surface area. In a patient who was nephrectomised, the peak level after intramuscular injection of 1 mg/kg gentamicin was 3·2 μg/ml, and T½ was 42 hours.

Developing a diagram. The values for T½ in Table 1 were plotted against the values for Ccr on log/log paper. They produced a straight line, and the regression equation was calculated to be 
y = 2.121 - 0.934x,
where x equals log (Ccr), and y equals log (T½). Fig. 1 shows the regression line

Table 1 Pharmacokinetics of gentamicin in patients with renal insufficiency

<table>
<thead>
<tr>
<th>Case no.</th>
<th>Age (years)</th>
<th>Weight (kg)</th>
<th>Clinical diagnosis</th>
<th>Ccr (ml/min per 1·73 m²)</th>
<th>Peak level (μg/ml)</th>
<th>Half-life (h)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>12</td>
<td>44</td>
<td>SLE-nephritis</td>
<td>148.0</td>
<td>9·4</td>
<td>1·2</td>
</tr>
<tr>
<td>2</td>
<td>14</td>
<td>50</td>
<td>Cystitis</td>
<td>123·0</td>
<td>6·0</td>
<td>1·3</td>
</tr>
<tr>
<td>3</td>
<td>10</td>
<td>35</td>
<td>Healthy</td>
<td>120·0</td>
<td>9·0</td>
<td>1·5</td>
</tr>
<tr>
<td>4</td>
<td>13</td>
<td>35</td>
<td>Purpuric nephritis</td>
<td>117·0</td>
<td>4·2</td>
<td>1·5</td>
</tr>
<tr>
<td>5</td>
<td>8</td>
<td>24</td>
<td>Nephrosis</td>
<td>115·0</td>
<td>3·8</td>
<td>1·4</td>
</tr>
<tr>
<td>6</td>
<td>12</td>
<td>27</td>
<td>SLE-nephritis</td>
<td>107·5</td>
<td>4·2</td>
<td>2·0</td>
</tr>
<tr>
<td>7</td>
<td>17</td>
<td>30</td>
<td>Chronic pyelonephritis</td>
<td>70·0</td>
<td>4·4</td>
<td>2·0</td>
</tr>
<tr>
<td>8</td>
<td>15</td>
<td>40</td>
<td>Chronic nephritis</td>
<td>64·0</td>
<td>6·3</td>
<td>3·1</td>
</tr>
<tr>
<td>9</td>
<td>13</td>
<td>38</td>
<td>SLE-nephritis</td>
<td>23·5</td>
<td>6·3</td>
<td>10·5</td>
</tr>
<tr>
<td>10</td>
<td>18</td>
<td>60</td>
<td>Chronic nephritis</td>
<td>18·1</td>
<td>3·9</td>
<td>11·7</td>
</tr>
<tr>
<td>11</td>
<td>16</td>
<td>50</td>
<td>SLE-nephritis</td>
<td>15·5</td>
<td>5·3</td>
<td>12·0</td>
</tr>
<tr>
<td>12</td>
<td>10</td>
<td>26·5</td>
<td>Chronic nephritis</td>
<td>14·4</td>
<td>6·3</td>
<td>6·4</td>
</tr>
<tr>
<td>13</td>
<td>10</td>
<td>23</td>
<td>Purpuric nephritis</td>
<td>9·5</td>
<td>3·1</td>
<td>16·1</td>
</tr>
<tr>
<td>14</td>
<td>13</td>
<td>30</td>
<td>Chronic nephritis</td>
<td>8·1</td>
<td>6·4</td>
<td>17·2</td>
</tr>
<tr>
<td>15</td>
<td>15</td>
<td>46</td>
<td>Chronic nephritis</td>
<td>5·0</td>
<td>4·2</td>
<td>27·0</td>
</tr>
</tbody>
</table>

SLE = systematic lupus erythematosus; Ccr = endogenous creatinine clearance.

Fig. 1 Correlation between creatinine clearance and serum half-life of gentamicin in 15 subjects. Upper and lower 95% confidence limits are shown.
Yoshioka, Takimoto, Matsuda, and Hattori

relating $T_{1/2}$ to Cr, with the calculated 95% confidence limits for individual patients. From this it is possible to predict the $T_{1/2}$ when the Cr of the patient is known. Thus, the diagram is of clinical importance, since it allows adjustment of the dosage interval of gentamicin in children with varying renal function.

**Testing the adjusted dosage schedule in clinical practice.** Infections due to Gram-negative bacteraemia in 3 children with renal disease were treated with the adjusted dosage schedule of gentamicin. Gentamicin was given to the patients in an intramuscular dosage of 1 mg/kg body weight and with the intervals estimated by Fig. 1. The data on these patients are given in Table 2. In Case A the dosage interval was set at 25 hours, and in Cases B and C at 13 hours. The time interval was 2-2 times as long as the estimated $T_{1/2}$ in Case A, and 3-5 and 3-7 times as long as those in Cases B and C, respectively.

The peak and blood level changes of gentamicin in these patients were followed up in the course of four repeated doses. Although the peak blood level varied in individual patients, it remained within 'therapeutic levels' and showed no tendency to accumulate (Fig. 2).

No signs of aggravating renal function, such as raised blood urea nitrogen or creatinine levels in plasma were observed and urinary examinations, including investigations of urinary sediment, showed no abnormalities throughout gentamicin treatment. No abnormalities in hearing or in vestibular function were observed in otological examinations performed before and after treatment.

**Discussion**

Gingell and Waterworth (1968) were the first to report that the half-life of gentamicin in serum correlated inversely with the rate of glomerular filtration as measured by renal creatinine clearance. In our study the half-life of gentamicin in our paediatric patients was shown to be significantly cor-

---

**Table 2 Patients treated by adjusted gentamicin dosage schedule**

<table>
<thead>
<tr>
<th>Case no.</th>
<th>Age (years)</th>
<th>Weight (kg)</th>
<th>Cr (ml/min per 1.73 m²)</th>
<th>Calculated $T_{1/2}$ (hours)</th>
<th>Intramuscular gentamicin</th>
<th>Dose (mg)</th>
<th>Interval (h)</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>13</td>
<td>44</td>
<td>13.9</td>
<td>11.3</td>
<td>gentamicin 44 mg</td>
<td>44</td>
<td>25</td>
</tr>
<tr>
<td>B</td>
<td>10</td>
<td>31</td>
<td>46.2</td>
<td>3.7</td>
<td>gentamicin 30 mg</td>
<td>30</td>
<td>13</td>
</tr>
<tr>
<td>C</td>
<td>12</td>
<td>32</td>
<td>48.6</td>
<td>3.5</td>
<td>gentamicin 30 mg</td>
<td>30</td>
<td>13</td>
</tr>
</tbody>
</table>
related with Ccr, in agreement with results obtained in adult patients.

The safe upper limit for the serum level of gentamicin is believed to be 10 \( \mu \text{g/ml} \). The minimum inhibitory concentrations of gentamicin to clinically significant Gram-negative organisms range from 0.5 to 4 \( \mu \text{g/ml} \) (Garrod et al., 1973). Thus, serum levels between 5 and 10 \( \mu \text{g/ml} \) are desirable and therapeutic, but not toxic. In our study peak serum levels ranging between 3-1 and 9-4 \( \mu \text{g/ml} \), with an average of 5-5 \( \mu \text{g/ml} \), were obtained after an intramuscular dosage of 1 mg/kg. These levels were clinically adequate; it rarely is necessary to administer gentamicin in excess of 1.0 mg/kg in these patients.

In order to avoid accumulation, the interval between doses of gentamicin must be prolonged in patients with renal impairment. It is desirable that the second dose be given when the serum level from the first dose falls to its lowest level. Theoretically, after an interval of twice the \( T_\frac{1}{2} \), the serum level is one-fourth of the peak serum level, and after three times \( T_\frac{1}{2} \) the serum level is one-eighth. The serum level may thus be predicted to be 1.0 \( \mu \text{g/ml} \) or less at these intervals after administration. It is generally accepted that drug accumulation does not take place if the interval between doses is greater than 1-44 times \( T_\frac{1}{2} \) (Gibaldi and Perrier, 1975). Gingell and Waterworth (1968) confirmed that administration of gentamicin at intervals of twice the calculated \( T_\frac{1}{2} \) is safe in a patient with a Ccr of 6-1 ml/min, and they proposed an interval of three times as long as the estimated \( T_\frac{1}{2} \) for adult renal insufficiency.

On the basis of our own observation we feel that their proposal is justifiable, and we recommend an interval of three times the \( T_\frac{1}{2} \) for paediatric patients as well. If the Ccr is known, the \( T_\frac{1}{2} \) can probably be estimated using Fig. 1. This method of calculation appeared satisfactory in 3 patients with renal insufficiency.

Although prediction of the serum level is possible, many investigators have reported that the peak levels as well as the half-life of gentamicin in serum may vary considerably in patients with comparable renal function (Gyselynck et al., 1971; Kaye et al., 1974). In difficult cases, therefore, it is advisable to determine the actual serum levels of the antibiotic whenever possible in order to achieve the anticipated therapeutic effects and to avoid toxicity.

References

Correspondence to Dr Hajime Yoshioka, Department of Paediatrics, Asahikawa Medical College, Kaguraoka 3-11, Kaguracho, 078-11 Asahikawa, Japan.
Dosage schedule of gentamicin for chronic renal insufficiency in children.
H Yoshioka, M Takimoto, I Matsuda and S Hattori

Arch Dis Child 1978 53: 334-337
doi: 10.1136/adc.53.4.334

Updated information and services can be found at:
http://adc.bmj.com/content/53/4/334

Email alerting service

These include:
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/